Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional)

The National Institutes of Health (NIH), specifically through the National Institute of Neurological Disorders and Stroke (NINDS), offers the funding opportunity titled "Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional)." This funding program, issued as PAR-24-098 and structured as a Small Business Innovation Research (SBIR) Cooperative Agreement (U44) under the Fast Track mechanism, aims to support the rigorous analytical validation of biomarkers that can enhance diagnostic or therapeutic strategies for neurological and neuromuscular conditions. This opportunity responds to the pressing need for robust biomarkers to aid in the development of treatments for challenging neurological diseases. It focuses on methodologically validating the analytic accuracy, sensitivity, specificity, and precision of biomarker detection methods. Eligible applicants must demonstrate the unmet need and scientific rationale for the biomarker, define one or two specific contexts of use, and provide evidence of preliminary testing. Applications should focus on optimizing and standardizing detection techniques, establishing performance thresholds, and incorporating multi-site validation where feasible. Funding supports Phase I budgets of up to $700,000 per year and Phase II budgets up to $1,500,000 per year, with project durations of up to 2 years and 3 years respectively. This mechanism is cooperative, meaning there is significant NIH involvement both prior to and following the award, including milestone review and protocol input. Projects should incorporate cross-disciplinary collaboration, leverage resources such as BioSEND, and include detailed plans for analytical validation metrics, data management, and intellectual property. Applications may be submitted by U.S.-based small business concerns (SBCs), including those majority-owned by venture capital or similar entities under defined conditions. Applicants must follow detailed NIH submission requirements through Grants.gov, ASSIST, or institutional systems. Letter of Intent (LOI) submissions are encouraged 30 days prior to the application deadline. Application cycles occur semiannually with deadlines on February 21 and June 20 in 2025 and 2026, and March 22 and June 21 in 2024. All applications must be submitted by 5:00 PM local time. Recurrence of this opportunity is confirmed, with the next expected cycle opening in February 2026. Funding decisions follow peer review and advisory council review timelines, with start dates approximately 9–12 months post submission. For pre-application consultation, applicants are encouraged to contact Dr. Carol Taylor-Burds at [email protected] or call 301-496-1779.